Business Wire

Allurion Technologies Announces Submission of US Premarket Approval (PMA) Application for its Flagship Elipse ® Gastric Balloon

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, an established leader in the development of innovative, proven, and trusted weight loss experiences, today announced the Premarket Approval (PMA) ...
Healio

Swallowable gastric balloon plus liraglutide induces 18.7% weight loss in obesity

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with obesity who received a novel gastric balloon ...
BioWorld

Allurion Technologies begins pivotal trial for its Elipse nonsurgical gastric balloon

Allurion Technologies has launched its ENLIGHTEN clinical study of Elipse, a weight loss balloon swallowed via capsule and filled with liquid through a catheter, thereby avoiding surgery for patients ...
Business Wire

First Multi-Center Study Combining the Allurion Program With GLP-1 Therapy Presented at the European Congress on Obesity

NATICK, Mass.--(BUSINESS WIRE)--Allurion, a company dedicated to ending obesity, today announced results from a new study that will be presented at the European Congress on Obesity exploring the use ...
Medscape

Obesity Drug With Swallowable Balloon Boosts Weight Loss

DUBLIN — A swallowable gastric balloon (Allurion Balloon, formerly known as Elipse) combined with daily subcutaneous injections of the glucagon-like peptide 1 (GLP-1) agonist liraglutide (Saxenda, ...